https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Rilzabrutinib Becomes First Approved BTK Inhibitor for Immune Thrombocytopenia

Rilzabrutinib Becomes First Approved BTK Inhibitor for Immune Thrombocytopenia

Rilzabrutinib gained FDA approval as the first BTK inhibitor for chronic immune thrombocytopenia, offering new hope for patients with persistent symptoms.

administrator

Related Articles